{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:33:43Z","timestamp":1790872423062,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.diagmicrobio.2007.06.001","type":"journal-article","created":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T11:31:00Z","timestamp":1191324660000},"page":"199-209","source":"Crossref","is-referenced-by-count":37,"title":["Zyvox\u00ae Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries"],"prefix":"10.1016","volume":"59","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijantimicag.2005.02.019","article-title":"Trends in linezolid susceptibility patterns: report from the 2002\u20132003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program","volume":"26","author":"Anderegg","year":"2005","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/313492","article-title":"Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms","volume":"29","author":"Antony","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/319986","article-title":"Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid","volume":"32","author":"Babcock","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1413-86702002000300001","article-title":"Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) Antimicrobial Potency Study in Latin America (LA-ZAPS)","volume":"6","author":"Ballow","year":"2002","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0732-8893(01)00334-0","article-title":"A multicenter evaluation of linezolid antimicrobial activity in North America","volume":"43","author":"Ballow","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jac\/dkg074","article-title":"Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific","volume":"51","author":"Bell","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib7","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1128\/JCM.35.12.3198-3202.1997","article-title":"Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents","volume":"35","author":"Biedenbach","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1469-0691.2002.00484.x","article-title":"Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe)","volume":"8","author":"Bolmstrom","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1469-0691.2004.01036.x","article-title":"Surveillance of linezolid resistance in Germany, 2001\u20132002","volume":"11","author":"Brauers","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/47.1.77","article-title":"In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates","volume":"47","author":"Cercenado","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"341","author":"Chen","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/313597","article-title":"Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections","volume":"30","author":"Chien","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib15","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A7","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib16","series-title":"Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A9","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib17","series-title":"Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement. M100-S17","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib18","series-title":"Microbiology Surveys Program; Critique for D-05, S. aureus","author":"College of American Pathologists","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib19","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib20","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.diagmicrobio.2006.01.003","article-title":"Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting","volume":"55","author":"Draghi","year":"2006","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib22","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.48.8.3169-3171.2004","article-title":"In vitro activities of telithromycin, linezolid, and quinupristin\u2013dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations","volume":"48","author":"Farrell","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijantimicag.2005.11.008","article-title":"Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis","volume":"27","author":"Gales","year":"2006","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/48.1.47","article-title":"Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison","volume":"48","author":"Gemmell","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/46.6.931","article-title":"Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group","volume":"46","author":"Henwood","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0732-8893(01)00235-8","article-title":"Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby\u2013Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States","volume":"40","author":"Jones","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0732-8893(01)00333-9","article-title":"Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program","volume":"42","author":"Jones","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/jac\/dki437","article-title":"Oxazolidinone susceptibility patterns in 2004: report from the Zyvox\u00ae Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations","volume":"57","author":"Jones","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/jac\/dkl271","article-title":"Linezolid resistance in coagulase-negative staphylococci","volume":"58","author":"Kelly","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med."},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2007.06.001_bib31","first-page":"ii9","article-title":"Linezolid in vitro: mechanism and antibacterial spectrum","volume":"51","author":"Livermore","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1086\/313669","article-title":"Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin\/dalfopristin)","volume":"30","author":"McNeil","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib33","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1086\/423841","article-title":"Antimicrobial resistance to linezolid","volume":"39","author":"Meka","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1086\/313897","article-title":"Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias","volume":"31","author":"Melzer","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-138-2-200301210-00015","article-title":"Linezolid: the first oxazolidinone antimicrobial","volume":"138","author":"Moellering","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0732-8893(02)00371-1","article-title":"Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998\u20132000","volume":"43","author":"Mutnick","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1345\/aph.1C437","article-title":"Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program","volume":"37","author":"Mutnick","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ijantimicag.2006.09.021","article-title":"Linezolid-based therapy in Staphylococcus epidermidis endocarditis","volume":"29","author":"Mylona","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/517221","article-title":"Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin","volume":"28","author":"Noskin","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib40","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1086\/344177","article-title":"Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium","volume":"35","author":"Pai","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib41","series-title":"American Society for Microbiology, 106th General Meeting Orlando","first-page":"20","article-title":"Mutation analysis of Staphylococcus aureus isolates demonstrating trailing linezolid (LZD) endpoints in microdilution MIC assays, Abstr A-088","author":"Poppe","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1086\/505114","article-title":"Epidemiological profile of linezolid-resistant coagulase-negative staphylococci","volume":"43","author":"Potoski","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib43","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1128\/AAC.48.9.3583-3585.2004","article-title":"Clinical-use\u2013associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin\u2013dalfopristin","volume":"48","author":"Raad","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib44","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1086\/374929","article-title":"Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid","volume":"36","author":"Rahim","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2004.12.013","article-title":"Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program","volume":"52","author":"Ross","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijantimicag.2006.09.025","article-title":"Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox\u00ae Annual Appraisal of Potency and Spectrum Study","volume":"29","author":"Ross","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib47","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib48","series-title":"American Society for Microbiology, 105th General Meeting","first-page":"171","article-title":"Evaluation of broth microdilution (BMD) and Etest (E) for determining in vitro activity of linezolid (LZ) against S. aureus (SA) and enterococci (EN), Abstr C-320","author":"Sahm","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib49","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib51","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.44.12.3408-3413.2000","article-title":"Randomized comparison of linezolid (PNU-100766) versus oxacillin\u2013dicloxacillin for treatment of complicated skin and soft tissue infections","volume":"44","author":"Stevens","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-0711-5-2","article-title":"Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States","volume":"5","author":"Styers","year":"2006","journal-title":"Ann. Clin. Microbiol. Antimicrobial."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib53","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib54","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib55","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1378\/chest.124.5.1789","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/321896","article-title":"Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature","volume":"33","author":"Zeana","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.06.001_bib57","author":"Zyvox Package Insert"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307002544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307002544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:02:04Z","timestamp":1587945724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889307002544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0732889307002544"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.06.001","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}